[Morbidity and mortality of infectious diseases determined mass vaccination in children under 5 ans in Bamako District].
Available facts on morbidity and mortality due to PEV diseases for children under 5 years come from routine facts in Bamako District. The Present study through population investigation proposed to evaluate indicators. It was about a transversal investigation realised about 1014 children less than 5 year living in Bamako (on October 2000). The selection of children has been made by boring after stratification of the district based on socio-economic level and stabilization of population of different sectors. According to study, the global incidence rate of target patients of PEV is about 4.93% +- 1.33%. These rate were about 4.14% +- 1.22% for measles which is the 1st cause of morbidity among target patients of PEV, 0.69% +- 0.50% for whooping cough, 0.903% +- 0.19 for poliomyelitis and 0% for neo natal tetanus. For tuberculosis of which evolution have been appreciated trough counting of antituberculosis clinic register (DAT) during 10 years (1990-1999), its tendency was increasing. The death rate registered during investigation was related to measles with an estimated rate of 4.93% +- 4.31%. Results analysis, global incidence of PEV target patients was in decrease at Bamako district. At vaccinated patients against measles (64.3%) and whooping cough (57.14%) is in favour for an investigation about effective vaccinal.
Maître Assistant en Santé publique a la FMPOS de Bamako.
A
A
Diawara
H
H
Sangho
H
H
Sango
M
M
Sacko
S
S
Sow
K
K
Toure
O
O
Doumbo
S Y
SY
Simaga
D001500:BCG Vaccine / Q000008:administration & dosage; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D003906:Developing Countries; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008302:Mali / Q000453:epidemiology; D032541:Mass Vaccination / Q000379:methods* / Q000458:organization & administration; D008457:Measles / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D022542:Measles-Mumps-Rubella Vaccine / Q000008:administration & dosage; D011051:Poliomyelitis / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D023321:Poliovirus Vaccines / Q000008:administration & dosage; D015995:Prevalence; D013742:Tetanus / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D014376:Tuberculosis / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D017778:Vaccines, Combined / Q000008:administration & dosage; D014917:Whooping Cough / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control
D001500:BCG Vaccine; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D023321:Poliovirus Vaccines; D017778:Vaccines, Combined